EMEA-000753-PIP01-11
Key facts
| Active substance |
Recombinant porcine factor VIII, B-domain deleted
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0040/2012
|
| PIP number |
EMEA-000753-PIP01-11
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of acquired haemophilia A
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Baxalta Innovations GmbH
E-mail: medinfoEMEA@takeda.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|